Menu Close

Trending

Data backs AZ’s Wilson disease drug, but with a question mark
Fujifilm acquires AI tech to improve fertility treatment
Sarepta shares yo-yo as FDA places hold on Duchenne trial
New countries stockpile antiviral TPOXX as monkeypox outbreak continues
Biogen and Happify partner on digital support for MS patients

Partner Content

2017.05.16 18_cropped

Market Access/ Partner Content/ Partner content/ Press releases

Industry experts set to transform evolving pre-approval & unlicensed medicines sector with launch of Inceptua Medicines Access

, , , , , 0 Comment

Created in response to unprecedented global demand from patients and physicians and to provide a long-sought after alternative

X
Industry experts set to transform evolving pre-approval & unlicensed medicines sector with launch of Inceptua Medicines Access
https://pharmaphorum.com/partner-content-market-access/industry-experts-set-transform-evolving-pre-approval-unlicensed-medicines-sector-launch-inceptua-medicines-access/

Market Access/ Partner Content/ Pharma Market Access/ Press releases

Orphan medicines, advances, access and affordability

, , , , , , , 0 Comment

LONDON, UNITED KINGDOM, April 19th 2017: The number of orphan drug candidates gaining European market authorisation has risen

X
Orphan medicines, advances, access and affordability
https://pharmaphorum.com/partner-content-market-access/orphan-medicines-advances-access-affordability/
Kantar_ASCO Day 4 coverage pic

ASCO-contributor/ Market Access/ Oncology/ Partner Content/ Partner Content/ Partner content/ Pharma Market Access/ Press releases

Does NEMO bring us a step closer in the fight against melanoma?

, , , , , , , 0 Comment

Options for treatment in metastatic melanoma have increased significantly in terms of efficacy and reduction of mortality in

X
Does NEMO bring us a step closer in the fight against melanoma?
https://pharmaphorum.com/partner-content-oncology/nemo-bring-us-step-closer-fight-melanoma/
Kantar_ASCO Day 4 coverage pic

ASCO-contributor/ Market Access/ Oncology/ Partner Content/ Partner content/ Partner Content/ Pharma Market Access/ Press releases

The HNSCC immunotherapy race is on – and it’s going to be close

, , , , , , 0 Comment

While improper to compare life saving treatments to buses – the metaphor when it comes to head and

X
The HNSCC immunotherapy race is on – and it’s going to be close
https://pharmaphorum.com/partner-content-oncology/hnscc-immunotherapy-race-going-close/
Kantar_ASCO Day 3 coverage pic

ASCO-contributor/ Market Access/ Oncology/ Partner Content/ Partner Content/ Partner content/ Pharma Market Access/ Press releases

Further Darzalex results extend hope for PFS in Myeloma

, , , , , 0 Comment

Earlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its

X
Further Darzalex results extend hope for PFS in Myeloma
https://pharmaphorum.com/partner-content-oncology/further-darzalex-results-extend-hope-for-pfs-in-myeloma/
Kantar_ASCO Day 2 coverage pic 1

ASCO-contributor/ Clinical/ Market Access/ Oncology/ Partner content/ Partner Content/ Partner Content/ Pharma Market Access/ Press releases

Positive PIII results for VYXEOS revealed at ASCO

, , , , , , , 0 Comment

Building on the announcement made in March of this year, Celator Pharmaceuticals has today (June 4th) presented the

X
Positive PIII results for VYXEOS revealed at ASCO
https://pharmaphorum.com/partner-content-oncology/positive-piii-results-for-vyxeos-revealed-at-asco/
«‹ 12 13 14 15

Login

CONTINUE TO SITE >
X
Close in 10 seconds